論文業績紹介

2024年

Nakamura R, Yamada T, Tokuda S, Morimoto K, Katayama Y, Matsui Y, Hirai S, Ishida M, Kawachi H, Sawada R, Tachibana Y, Osoegawa A, Horinaka M, Sakai T, Yasuhiro T, Kozaki R, Yano S, Takayama K. Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cance. Cancer Lett. 598:217124, 2024.

Matsui Y, Yamada T, Katayama Y, Hirai S, Sawada R, Tachibana Y, Ishida M, Kawachi H, Nakamura R, Nishioka N, Morimoto K, Iwasaku M, Horinaka M, Sakai T, Tokuda S, Takayama K. Initial AXL and MCL-1 inhibition contributes to abolishing lazertinib tolerance in EGFR-mutant lung cancer cells. Cancer Sci. Online ahead of print, 2024.

Yoshimura A, Horinaka M, Yaoi T, Ono H, Itoh K, Yamada T, Takayama K, Sakai T. Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer. Br J Cancer. 131:361-71, 2024.

Morimoto K, Yamada T, Hirai S, Katayama Y, Fukui S, Sawada R, Tachibana Y, Matsui Y, Nakamura R, Ishida M, Kawachi H, Kunimasa K, Sasaki T, Nishida M, Furuya N, Watanabe S, Shiotsu S, Nishioka N, Horinaka M, Sakai T, Uehara H, Yano S, Son BK, Tokuda S, Takayama K. AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells. Cancer Lett. 587:216692, 2024.

Ota Y, Itoh Y, Takada Y, Yamashita Y, Hu C, Horinaka M, Sowa Y, Masuda M, Sakai T, Suzuki T. Design, synthesis, and biological evaluation of phenylcyclopropylamine-entinostat conjugates that selectively target cancer cells. Bioorg Med Chem. 100:117632, 2024.

Hirai S, Yamada T, Katayama Y, Ishida M, Kawachi H, Matsui Y, Nakamura R, Morimoto K, Horinaka M, Sakai T, Sekido Y, Tokuda S, Takayama K. Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells. Mol Cancer Ther. 23:212-22, 2024.

2023年

Itoh Y, Zhan P, Tojo T, Jaikhan P, Ota Y, Suzuki M, Li Y, Hui Z, Moriyama Y, Takada Y, Yamashita Y, Oba M, Uchida S, Masuda M, Ito S, Sowa Y, Sakai T, Suzuki T. Discovery of Selective Histone Deacetylase 1 and 2 Inhibitors: Screening of a Focused Library Constructed by Click Chemistry, Kinetic Binding Analysis, and Biological Evaluation. J Med Chem. 66:15171-88, 2023.

Masuda M, Horinaka M, Yasuda S, Morita M, Nishimoto E, Ishikawa H, Mutoh M, Sakai T. Discovery of cancer-preventive juices reactivating RB functions. Environ Health Prev Med. 28:54, 2023.

Nohara Y, Taniguchi K, Ii H, Masuda S, Kawakami H, Matsumoto M, Hattori Y, Kageyama S, Sakai T, Nakata S, Yoshiya T. Development of an activity-based chemiluminogenic probe for γ-glutamylcyclotransferase. Org Biomol Chem. 21:5977-84, 2023.

Saito Y, Taniguchi K, Ii H, Horinaka M, Kageyama S, Nakata S, Ukimura O, Sakai T. Identification of c-Met as a novel target of γ-glutamylcyclotransferase. Sci Rep. 13:11922, 2023.

Katayama Y, Yamada T, Tanimura K, Tokuda S, Morimoto K, Hirai S, Matsui Y, Nakamura R, Ishida M, Kawachi H, Yoneda K, Hosoya K, Tsuji T, Ozasa H, Yoshimura A, Iwasaku M, Kim YH, Horinaka M, Sakai T, Utsumi T, Shiotsu S, Takeda T, Katayama R, Takayama K. Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer. NPJ Precis Oncol. 7:12, 2023.

2022年

Imai A, Horinaka M, Aono Y, Iizumi Y, Takakura H, Ono H, Yasuda S, Taniguchi K, Nishimoto E, Ishikawa H, Mutoh M, Sakai T. Salicylic acid directly binds to ribosomal protein S3 and suppresses CDK4 expression in colorectal cancer cells. Biochem Biophys Res Commun. 628:110-15, 2022.

Ii H, Taniguchi K, Yoshiya T, Nohara Y, Kageyama S, Kawauchi A, Nakata S. The γ-Glutamylcyclotransferase Inhibitor Pro-GA Induces an Antiproliferative Effect Through the Generation of Mitochondrial Reactive Oxygen Specie. Anticancer Res. 42:4311-17, 2022.

Ota Y, Itoh Y, Kurohara T, Singh R, Elboray EE, Hu C, Zamani F, Mukherjee A, Takada Y, Yamashita Y, Morita M, Horinaka M, Sowa Y, Masuda M, Sakai T, Suzuki T. Cancer-Cell-Selective Targeting by Arylcyclopropylamine-Vorinostat Conjugates. ACS Med Chem Lett. 13:1568-73, 2022.

Sakai T. “RB-reactivator screening” as a novel cell-based assay for discoveries of molecular targeting agents including the first-in-class MEK inhibitor trametinib (trade name: Mekinist). Pharmacol Ther. 236:108234, 2022.

Takakura H, Nakao T, Narita T, Horinaka M, Nakao-Ise Y, Yamamoto T, Iizumi Y, Watanabe M, Sowa Y, Oda K, Mori N, Sakai T, Mutoh M. Citrus limonL.-Derived Nanovesicles Show an Inhibitory Effect on Cell Growth in p53-Inactivated Colorectal Cancer Cells via the Macropinocytosis Pathway. Biomedicines. 10:1352, 2022.

Iizumi Y, Sowa Y, Goi W, Aono Y, Watanabe M, Kurumida Y, Kameda T, Akaji K, Kitagawa M, Sakai T. Stabilization of CDK6 by ribosomal protein uS7, a target protein of the natural product fucoxanthinol. Commun Biol. 5:564, 2022.

Mure K, Ishikawa H, Mutoh M, Horinaka M, Otani T, Suzuki S, Wakabayashi K, Sakai T, J-FAPP Study IV group. Efficacy of Low-Dose Aspirin in Colorectal Cancer Risk Prevention is Dependent on ADH1B and ALDH2 Genotype in Japanese Familial Adenomatous Polyposis Patients. Cancer Res Commun. 2:483-88, 2022.

Watanabe M, Boku S, Kobayashi K, Kurumida Y, Sukeno M, Masuda M, Mizushima K, Kato C, Iizumi Y, Hirota K, Naito Y, Mutoh M, Kameda T, Sakai T. A chemoproteoinformatics approach demonstrates that aspirin increases sensitivity to MEK inhibition by directly binding to RPS5. PNAS Nexus. 1:pgac059, 2022.

Takakura H, Horinaka M, Imai A, Aono Y, Nakao T, Miyamoto S, Iizumi Y, Watanabe M, Narita T, Ishikawa H, Mutoh M, Sakai T. Sodium salicylate and 5-aminosalicylic acid synergistically inhibit the growth of human colon cancer cells and mouse intestinal polyp-derived cells. J Clin Biochem Nutr. 70:93-102, 2022.

Moyama C, Fujita M, Ando S, Taniguchi K, Ii H, Tanigawa S, Hashimoto N, Nakata S. Stat5b inhibition blocks proliferation and tumorigenicity of glioblastoma stem cells derived from a de novo murine brain cancer model. Am J Cancer Res. 12:1129-42, 2022.

Isa R, Horinaka M, Tsukamoto T, Mizuhara K, Fujibayashi Y, Taminishi-Katsuragawa Y, Okamoto H, Yasuda S, Kawaji-Kanayama Y, Matsumura-Kimoto Y, Mizutani S, Shimura Y, Taniwaki M, Sakai T, Kuroda J. The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma. Int J Mol Sci. 23:2919, 2022.

Katayama Y, Yamada T, Tokuda S, Okura N, Nishioka N, Morimoto K, Tanimura K, Morimoto Y, Iwasaku M, Horinaka M, Sakai T, Kita K, Yano S, Takayama K. Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR-T790M mutation in non-small cell lung cancer cells. Cancer Med. 11:944-55, 2022.

Kaneda D, Iehara T, Kikuchi K, Sugimoto Y, Nakagawa N, Yagyu S, Miyachi M, Konishi E, Sakai T, Hosoi H. The histone deacetylase inhibitor OBP-801 has in vitro/in vivo anti-neuroblastoma activity. Pediatr Int. 64:e15159, 2022.

Yoshida T, Yamasaki K, Tadagaki K, Kuwahara Y, Matsumoto A, Sofovic AE, Kondo N, Sakai T, Okuda T. Tumor necrosis factor‑related apoptosis‑inducing ligand is a novel transcriptional target of runt‑related transcription factor 1. Int J Oncol. 60:6, 2022.

Tanimura K, Yamada T, Okada K, Nakai K, Horinaka M, Katayama Y, Morimoto K, Ogura Y, Takeda T, Shiotsu S, Ichikawa K, Watanabe S, Morimoto Y, Iwasaku M, Kaneko Y, Uchino J, Taniguchi H, Yoneda K, Matoba S, Sakai T, Uehara H, Yano S, Kusaba T, Katayama R, Takayama K. HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features. NPJ Precis Oncol. 6:5, 2022.

Yasuda S, Horinaka M, Iizumi Y, Goi W, Sukeno M, Sakai T. Oridonin inhibits SASP by blocking p38 and NF-κB pathways in senescent cells. Biochem Biophys Res Commun. 590:55-62, 2022.

Taniguchi K, Kageyama S, Moyama C, Ando S, Ii H, Ashihara E, Horinaka M, Sakai T, Kubota S, Kawauchi A, Nakata S. γ-Glutamylcyclotransferase, a novel regulator of HIF-1α expression, triggers aerobic glycolysis. Cancer Gene Ther. 29:37-48, 2022.

Masuzawa R, Takahashi K, Takano K, Nishino I, Sakai T, Endo T. DA-Raf and the MEK inhibitor trametinib reverse skeletal myocyte differentiation inhibition or muscle atrophy caused by myostatin and GDF11 through the non-Smad Ras-ERK pathway. J Biochem. 171:109-22, 2022.

2021年

Ono H, Horinaka M, Sukeno M, Morita M, Yasuda S, Nishimoto E, Konishi E, Sakai T. Novel RAF/MEK inhibitor CH5126766/VS-6766 has efficacy in combination with eribulin for the treatment of triple-negative breast cancer. Cancer Sci. 112:4166-75, 2021.

Tanimura K, Yamada T, Horinaka M, Katayama Y, Fukui S, Morimoto K, Nakano T, Tokuda S, Morimoto Y, Iwasaku M, Kaneko Y, Uchino J, Yoneda K, Yano S, Sakai T, Takayama K. Inhibition of c-Jun N-terminal kinase signaling increased apoptosis and prevented the emergence of ALK-TKI-tolerant cells in ALK-rearranged non-small cell lung cancer. Cancer Lett. 522:119-28, 2021.

Mure K, Tomono S, Mure M, Horinaka M, Mutoh M, Sakai T, Ishikawa H, Wakabayashi K. The combination of cigarette smoking and alcohol consumption synergistically increases reactive carbonyl species in human male plasma. Int J Mol Sci. 22:9043, 2021.

Ishikawa H, Mutoh M, Sato Y, Doyama H, Tajika M, Tanaka S, Horimatsu T, Takeuchi Y, Kashida H, Tashiro J, Ezoe Y, Nakajima T, Ikematsu H, Hori S, Suzuki S, Otani T, Takayama T, Ohda Y, Mure K, Wakabayashi K, Sakai T. Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial. Lancet Gastroenterol Hepatol. 2021.

Watanabe M, Yamada Y, Kurumida Y, Kameda T, Sukeno M, Iizuka-Ohashi M, Sowa Y, Iizumi Y, Takakura H, Miyamoto S, Sakai T, Mutoh M. Rabdosianone I, a bitter diterpene from an oriental herb, suppresses thymidylate synthase expression by directly binding to ANT2 and PHB2. Cancers (Basel). 13:982, 2021.

Hamoya T, Fujii G, Iizumi Y, Narita T, Komiya M, Matsuzawa Y, Miki K, Kondo T, Kishimoto S, Watanabe K, Wakabayashi K, Sakai T, Toshima J, Mutoh M. Artesunate inhibits intestinal tumorigenesis through inhibiting wnt signaling. Carcinogenesis. 42:148-58, 2021.

2020年

Sugimoto Y, Katsumi Y, Iehara T, Kaneda D, Tomoyasu C, Ouchi K, Yoshida H, Miyachi M, Yagyu S, Kikuchi K, Tsuchiya K, Kuwahara Y, Sakai T, Hosoi H. The novel histone deacetylase inhibitor, OBP-801, induces apoptosis in rhabdoid tumors by releasing the silencing of NOXA. Mol Cancer Ther. 19:1992-2000, 2020.

Mutoh M, Yoshimura K, Fujii G, Nakamura T, Takeshita T, Wakabayashi K, Sakai T, Ishikawa H. Very long-term treatment with a Lactobacillus probiotic preparation, Lactobacillus casei strain Shirota, suppresses weight loss in the elderly. Nutrients. 12:1599, 2020.

Okura N, Nishioka N, Yamada T, Taniguchi H, Tanimura K, Katayama Y, Yoshimura A, Watanabe S, Kikuchi T, Shiotsu S, Kitazaki T, Nishiyama A, Iwasaku M, Kaneko Y, Uchino J, Uehara H, Horinaka M, Sakai T, Tanaka K, Kozaki R, Yano S, Takayama K. ONO-7475, a novel AXL inhibitor, suppresses the adaptive resistance to initial EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer. Clin Cancer Res. 26:2244-56, 2020.

Boku S, Watanabe M, Sukeno M, Yaoi T, Hirota K, Iizuka-Ohashi M, Itoh K, Sakai T. Deactivation of glutaminolysis sensitizes PIK3CA-mutated colorectal cancer cells to aspirin-induced growth inhibition. Cancers (Basel). 12:E1097, 2020.

Umemura S, Sowa Y, Iizumi Y, Kitawaki J, Sakai T. Synergistic effect of the inhibitors of RAF/MEK and AXL on KRAS-mutated ovarian cancer cells with high AXL expression.
Cancer Sci. 111:2052-61, 2020.

Kawarazaki A, Horinaka M, Yasuda S, Kawashima H, Numajiri T, Sakai T. The HDAC inhibitor OBP-801 suppresses the growth of myxofibrosarcoma cells. J BUON. 25:464-71, 2020.

Miyamoto K, Watanabe M, Boku S, Sukeno M, Morita M, Kondo H, Sakaguchi K, Taguchi T, Sakai T. xCT inhibition increases sensitivity to vorinostat in a ROS-dependent manner.
Cancers (Basel). 12:827, 2020.

Chihara Y, Iizumi Y, Horinaka M, Watanabe M, Goi W, Morita M, Nishimoto E, Sowa Y, Yamada T, Takayama K, Sakai T. Histone deacetylase inhibitor OBP‑801 and amrubicin synergistically inhibit the growth of squamous cell lung carcinoma by inducing mitochondrial ASK1‑dependent apoptosis. Int J Oncol. 56:848-56, 2020.

2019年

Yasuda S, Horinaka M, Sakai T. Sulforaphane enhances apoptosis induced by Lactobacillus pentosus strain S-PT84 via the TNFα pathway in human colon cancer cells. Oncol Lett. 18:4253-61, 2019.

Yasuda S, Sowa Y, Hashimoto H, Nakagami T, Tsuno T, Sakai T. Cycloartenyl ferulate and β-sitosteryl ferulate-steryl ferulates of γ-oryzanol-suppress intracellular reactive oxygen species in cell-based system. J Oleo Sci. 68:765-8, 2019.

Nakamura T, Ishikawa H, Sakai T, Ayabe M, Wakabayashi K, Mutoh M, Matsuura N. Effect of physical fitness on colorectal tumor development in patients with familial adenomatous polyposis. Medicine (Baltimore). 98:e17076, 2019.

Ishikawa H, Mutoh M, Abe T, Nakajima T, Takeuchi Y, Ezoe Y, Wakabayashi K, Doyama H, Sakai T. Utility of mesalazine in familial adenomatous polyposis: Clinical report of reduction of polyp size in patients with ulcerative colitis, and safety examination in familial adenomatous polyposis patients. Pharmacology. 104:51-6, 2019.

Shiotani A, Ishikawa H, Mutoh M, Takeshita T, Nakamura T, Morimoto K, Sakai T, Wakabayashi K, Matsuura N. Impact of diarrhea after drinking on colorectal tumor risk: A case control study. Asian Pac J Cancer Prev. 20:795-9, 2019.

Nakagawa N, Kikuchi K, Yagyu S, Miyachi M, Iehara T, Tajiri T, Sakai T, Hosoi H. Mutations in the RAS pathway as potential precision medicine targets in treatment of rhabdomyosarcoma. Biochem Biophys Res Commun. 512:524-30, 2019.

Tomoyasu C, Kikuchi K, Kaneda D, Yagyu S, Miyachi M, Tsuchiya K, Iehara T, Sakai T, Hosoi H. OBP‑801, a novel histone deacetylase inhibitor, induces M‑phase arrest and apoptosis in rhabdomyosarcoma cells. Oncol Rep. 41:643-9, 2019.

2018年

Aono Y, Horinaka M, Iizumi Y, Watanabe M, Taniguchi T, Yasuda S, Sakai T. Sulindac sulfone inhibits the mTORC1 pathway in colon cancer cells by directly targeting voltage-dependent anion channel 1 and 2. Biochem Biophys Res Commun. 505:1203-10, 2018.

Hagiwara N, Watanabe M, Iizuka-Ohashi M, Yokota I, Toriyama S, Sukeno M, Tomosugi M, Sowa Y, Hongo F, Mikami K, Soh J, Fujito A, Miyashita H, Morioka Y, Miki T, Ukimura O, Sakai T. Mevalonate pathway blockage enhances the efficacy of mTOR inhibitors with the activation of retinoblastoma protein in renal cell carcinoma. Cancer Lett. 431:182-9, 2018.

Ono H, Sowa Y, Horinaka M, Iizumi Y, Watanabe M, Morita M, Nishimoto E, Taguchi T, Sakai T. The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway. Breast Cancer Res Treat. 171:43-52, 2018.

Iizuka-Ohashi M, Watanabe M, Sukeno M, Morita M, Hoang NTH, Kuchimaru T, Kizaka-Kondoh S, Sowa Y, Sakaguchi K, Taguchi T, Sakai T. Blockage of the mevalonate pathway overcomes the apoptotic resistance to MEK inhibitors with suppressing the activation of Akt in cancer cells. Oncotarget. 9:19597-612, 2018.

Takamura T, Horinaka M, Yasuda S, Toriyama S, Aono Y, Sowa Y, Miki T, Ukimura O, Sakai T. FGFR inhibitor BGJ398 and HDAC inhibitor OBP-801 synergistically inhibit cell growth and induce apoptosis in bladder cancer cells. Oncol Rep. 39:627-32, 2018.

Takeuchi Y, Tanaka T, Higashi M, Fumino S, Iehara T, Hosoi H, Sakai T, Tajiri T. In vivo effects of short- and long-term MAPK pathway inhibition against neuroblastoma. J Pediatr Surg. 53:2454-9, 2018.

Kawano A, Ishikawa H, Mutoh M, Kubota H, Matsuda K, Tsuji H, Matsumoto K, Nomoto K, Tanaka R, Nakamura T, Wakabayashi K, Sakai T. Higher enterococcus counts indicate a lower risk of colorectal adenomas: a prospective cohort study. Oncotarget. 9:21459-67, 2018.

Ota Y, Miyamura S, Araki M, Itoh Y, Yasuda S, Masuda M, Taniguchi T, Sowa Y, Sakai T, Itami K, Yamaguchi J, Suzuki T. Design, synthesis and evaluation of γ-turn mimetics as LSD1-selective inhibitors. Bioorg Med Chem. 26:775-85, 2018.

2017年

Ono H, Iizumi Y, Goi W, Sowa Y, Taguchi T, Sakai T. Ribosomal protein S3 regulates XIAP expression independently of the NF-κB pathway in breast cancer cells. Oncol Rep. 38:3205-10, 2017.

Watanabe M, Iizumi Y, Sukeno M, Iizuka-Ohashi M, Sowa Y, Sakai T. The pleiotropic regulation of cyclin D1 by newly identified sesaminol-binding protein ANT2. Oncogenesis. 6:e311, 2017.

Sakai T, Sowa Y. Molecular-targeting therapies against quantitative abnormalities in gene expression with malignant tumors. Cancer Sci. 108:570-3, 2017.

Kawarazaki A, Horinaka M, Yasuda S, Numajiri T, Nishino K, Sakai T. Sulforaphane suppresses cell growth and collagen expression of keloid fibroblasts. Wound Repair Regen. 25:224-33, 2017.

Akiyama M, Sowa Y, Taniguchi T, Watanabe M, Yogosawa S, Kitawaki J, Sakai T. Three-Combined Treatment, a Novel HDAC Inhibitor OBP-801/YM753, 5-Fluorouracil and Paclitaxel, Induces G2-Phase Arrest Through the p38 Pathway in Human Ovarian Cancer Cells. Oncol Res. 25:1245-52, 2017.

2016年

Tanaka R, Tomosugi M, Sakai T, Sowa Y. MEK inhibitor suppresses expression of the miR-17-92 cluster with G1-phase arrest in HT-29 human colon cancer cells and MIA PaCa-2 pancreatic cancer cells. Anticancer Res. 36:4537-43, 2016.

Nakamura T, Ishikawa H, Mutoh M, Wakabayashi K, Kawano A, Sakai T, Matsuura N. Coffee prevents proximal colorectal adenomas in Japanese men: a prospective cohort study. Eur J Cancer Prev. 25:388-94, 2016.

Toriyama S, Horinaka M, Yasuda S, Taniguchi T, Aono Y, Takamura T, Morioka Y, Miki T, Ukimura O, Sakai T. A histone deacetylase inhibitor OBP-801 and celecoxib synergistically inhibit the cell growth with apoptosis via a DR5-dependent pathway in bladder cancer cells. Mol Cancer Ther. 15:2066-75, 2016.

Taniguchi T, Iizumi Y, Watanabe M, Masuda M, Morita M, Aono Y, Toriyama S, Oishi M, Goi W, Sakai T. Resveratrol directly targets DDX5 resulting in suppression of the mTORC1 pathway in prostate cancer. Cell Death Dis. 7:e2211, 2016.

Ikai A, Watanabe M, Sowa Y, Kishimoto M, Yanagisawa A, Fujiwara H, Otsuji E, Sakai T. Phosphorylated retinoblastoma protein is a potential predictive marker of irinotecan efficacy for colorectal cancer. Int J Oncol. 48:1297-304, 2016.

Ishikawa H, Mutoh M, Iwama T, Suzuki S, Abe T, Takeuchi Y, Nakamura T, Ezoe Y, Fujii G, Wakabayashi K, Nakajima T, Sakai T. Endoscopic management of familial adenomatous polyposis in patients refusing colectomy. Endoscopy. 48:51-5, 2016.

Ota Y, Itoh Y, Kaise A, Ohta K, Endo Y, Masuda M, Sowa Y, Sakai T, Suzuki T. Targeting cancer with PCPA-drug conjugates: LSD1 inhibition-triggered release of 4-hydroxytamoxifen. Angew Chem Int Ed Engl. 55:16115-8, 2016.

Tanaka T, Higashi M, Kimura K, Wakao J, Fumino S, Iehara T, Hosoi H, Sakai T, Tajiri T. MEK inhibitors as a novel therapy for neuroblastoma: Their in vitro effects and predicting their efficacy. J Pediatr Surg. 2016 51:2074-9, 2016.

Uchino S, Ishikawa H, Miyauchi A, Hirokawa M, Noguchi S, Ushiama M, Yoshida T, Michikura M, Sugano K, Sakai T. Age- and gender-specific risk of thyroid cancer in patients with familial adenomatous polyposis. J Clin Endocrinol Metab. 101:4611-7, 2016.

Miyamura S, Araki M, Ota Y, Itoh Y, Yasuda S, Masuda M, Taniguchi T, Sowa Y, Sakai T, Suzuki T, Itami K, Yamaguchi J. C-H activation enables a rapid structure-activity relationship study of arylcyclopropyl amines for potent and selective LSD1 inhibitors. Org Biomol Chem. 14:8576-85, 2016.

Fujiwara J, Sowa Y, Horinaka M, Koyama M, Wakada M, Miki T, Sakai T. The anti-obesity drug orlistat promotes sensitivity to TRAIL by two different pathways in hormone-refractory prostate cancer cells. Int J Oncol. 48:854, 2016.

2015年

Ichikawa M, Sowa Y, Iizumi Y, Aono Y, Sakai T. Resibufogenin Induces G1-Phase Arrest through the Proteasomal Degradation of Cyclin D1 in Human Malignant Tumor Cells. PLoS One. 10:e0129851, 2015.

Tanaka R, Tomosugi M, Horinaka M, Sowa Y, Sakai T. Metformin Causes G1-Phase Arrest via Down-Regulation of MiR-221 and Enhances TRAIL Sensitivity through DR5 Up-Regulation in Pancreatic Cancer Cells. PLoS One. 10:e0125779, 2015.

Wada M, Horinaka M, Yasuda S, Masuzawa M, Sakai T, Katoh N. PDK1 is a potential therapeutic target against angiosarcoma cells. J Dermatol Sci. 78:44-50, 2015.

Sun Q, Yogosawa S, Iizumi Y, Sakai T, Sowa Y.The alkaloid emetine sensitizes ovarian carcinoma cells to cisplatin through downregulation of bcl-xL. Int J Oncol. 46:389-94, 2015.

Goda AE, Erikson RL, Sakai T, Ahn JS, Kim BY. Preclinical evaluation of bortezomib/dipyridamole novel combination as a potential therapeutic modality for hematologic malignancies. Mol Oncol. 9:309-22, 2015.

Shiotani A, Ishikawa H, Mutoh M, Takeshita T, Nakamura T, Morimoto K, Sakai T, Wakabayashi K, Matsuura N. Genetic Polymorphisms in ADH1B and ALDH2 Are Associated with Colorectal
Tumors in Japan: A Case-Control Study. Journal of Cancer Therapy. 6:1054-62, 2015.

2014年

Wada M, Horinaka M, Yamazaki T, Katoh N, Sakai T. The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells. PLoS One. 9:e113217, 2014.

Horinaka M, Yoshida T, Tomosugi M, Yasuda S, Sowa Y, Sakai T. Myeloid zinc finger 1 mediates sulindac sulfide-induced upregulation of death receptor 5 of human colon cancer cells. Sci Rep. 4:6000, 2014.

Furutani A, Sowa Y, Fujiwara H, Otsuji E, Sakai T. The novel HDAC inhibitor OBP-801/YM753 enhances the effects of 5-fluorouracil with radiation on esophageal squamous carcinoma cells. Oncol Res. 21:281-6, 2014.

Kotoku N, Higashimoto K, Kurioka M, Arai M, Fukuda A, Sumii Y, Sowa Y, Sakai T, Kobayashi M. Xylarianaphthol-1, a novel dinaphthofuran derivative, activates p21 promoter in a p53-independent manner. Bioorg Med Chem Lett. 24:3389-91, 2014.

Ishikawa H, Mutoh M, Suzuki S, Tokudome S, Saida Y, Abe T, Okamura S, Tajika M, Joh T, Tanaka S, Kudo SE, Matsuda T, Iimuro M, Yukawa T, Takayama T, Sato Y, Lee K, Kitamura S, Mizuno M, Sano Y, Gondo N, Sugimoto K, Kusunoki M, Goto C, Matsuura N, Sakai T, Wakabayashi K. The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial. Gut. 63:1755-9, 2014.

Koyama M, Sowa Y, Horinaka M, Goda AE, Fujiwara J, Sakai T. Peroxisome proliferator-activated receptor γ ligand troglitazone and TRAIL synergistically induce apoptosis. Oncol Rep. 31:947-54, 2014.

Okumura N, Nakano S, Kay EP, Numata R, Ota A, Sowa Y, Sakai T, Ueno M, Kinoshita S, Koizumi N. Involvement of cyclin D and p27 in cell proliferation mediated by ROCK inhibitors Y-27632 and Y-39983 during corneal endothelium wound healing. Invest Ophthalmol Vis Sci. 55:318-29, 2014.

Hongo F, Takaha N, Oishi M, Ueda T, Nakamura T, Naitoh Y, Naya Y, Kamoi K, Okihara K, Matsushima T, Nakayama S, Ishihara H, Sakai T, Miki T. CDK1 and CDK2 activity is a strong predictor of renal cell carcinoma recurrence. Urol Oncol. 32:1240-6, 2014.

2013年

Koyama M, Sowa Y, Hitomi T, Iizumi Y, Watanabe M, Taniguchi T, Ichikawa M, Sakai T. Perillyl alcohol causes G1 arrest through p15(INK4b) and p21(WAF1/Cip1) induction. Oncol Rep. 29:779-84, 2013.

Iizumi Y, Oishi M, Taniguchi T, Goi W, Sowa Y, Sakai T. The flavonoid apigenin downregulates CDK1 by directly targeting ribosomal protein S9. PLoS One. 8:e73219, 2013.

Ishikawa H, Wakabayashi K, Suzuki S, Mutoh M, Hirata K, Nakamura T, Takeyama I, Kawano A, Gondo N, Abe T, Tokudome S, Goto C, Matsuura N, Sakai T. Preventive effects of low-dose aspirin on colorectal adenoma growth in patients with familial adenomatous polyposis: double-blind, randomized clinical trial. Cancer Med. 2: 50-6, 2013.

Todo M, Horinaka M, Tomosugi M, Tanaka R, Ikawa H, Sowa Y, Ishikawa H, Fujiwara H, Otsuji E, Sakai T. Ibuprofen enhances TRAIL-induced apoptosis through DR5 upregulation. Oncol Rep. 30: 2379-84, 2013.

Yamada T, Horinaka M, Shinnoh M, Yoshioka T, Miki T, Sakai T. A novel HDAC inhibitor OBP-801 and a PI3K inhibitor LY294002 synergistically induce apoptosis via the suppression of survivin and XIAP in renal cell carcinoma. Int J Oncol. 43: 1080-6, 2013.

Ishii N, Harada N, Joseph EW, Ohara K, Miura T, Sakamoto H, Matsuda Y, Tomii Y, Tachibana-Kondo Y, Iikura H, Aoki T, Shimma N, Arisawa M, Sowa Y, Poulikakos PI, Rosen N, Aoki Y, Sakai T. Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity. Cancer Res. 73:4050-60, 2013.

Goda AE, Koyama M, Sowa Y, Elokely KM, Yoshida T, Kim BY, Sakai T. Molecular mechanisms of the antitumor activity of SB225002: a novel microtubule inhibitor. Biochem Pharmacol. 85: 1741-52, 2013.

Watanabe M, Sowa Y, Yogosawa M, Sakai T. Novel MEK inhibitor trametinib and other retinoblastoma gene (RB)-reactivating agents enhance efficacy of 5-fluorouracil on human colon cancer cells. Cancer Sci. 104:687-93, 2013.

Oishi M, Iizumi Y, Taniguchi T, Goi W, Miki T, Sakai T. Apigenin sensitizes prostate cancer cells to Apo2L/TRAIL by targeting adenine nucleotide translocase-2. PLoS One. 8: e55922, 2013.

Yoshioka T, Yogosawa S, Yamada T, Kitawaki J, Sakai T. Combination of a novel HDAC inhibitor OBP-801/YM753 and a PI3K inhibitor LY294002 synergistically induces apoptosis in human endometrial carcinoma cells due to increase of Bim with accumulation of ROS. Gynecol Oncol. 129: 425-32, 2013.

Shinnoh M, Horinaka M, Yasuda T, Yoshikawa S, Morita M, Yamada T, Miki T, Sakai T. Clostridium butyricum MIYAIRI 588 shows antitumor effects by enhancing the release of TRAIL from neutrophils through MMP-8. Int J Oncol. 42: 903-11, 2013.

2012年

Ishikawa H, Goto M, Matsuura N, Murakami Y, Goto C, Sakai T, Kanazawa K. A pilot, randomized, placebo-controlled, double-blind phase 0/biomarker study on effect of artepillin C-rich extract of Brazilian propolis in frequent colorectal adenoma polyp patients. J Am Coll Nutr. 31: 327-37, 2012.

Yogosawa S, Yamada Y, Yasuda S, Sun Q, Takizawa K, Sakai T. Dehydrozingerone, a structural analogue of curcumin, induces cell-cycle arrest at the G2/M phase and accumulates intracellular ROS in HT-29 human colon cancer cells. J Nat Prod. 75: 2088-93, 2012.

Yoshida T, Kakegawa J, Yamaguchi T, Hantani Y, Okajima N, Sakai T, Watanabe Y, Nakamura M. Identification and characterization of a novel chemotype MEK inhibitor able to alter the phosphorylation state of MEK1/2. Oncotarget. 3: 1533-45, 2012.

Tomosugi M, Sowa Y, Yasuda S, Tanaka R, te Riele H, Ikawa H, Koyama M, Sakai T. Retinoblastoma gene-independent G1 phase arrest by flavone, phosphatidylinositol 3-kinase inhibitor, and histone deacetylase inhibitor. Cancer Sci. 2012, 103: 2139-43.

Tophkhane C, Yang SH, Jiang Y, Ma Z, Subramaniam D, Anant S, Yogosawa S, Sakai T, Liu WG, Edgerton S, Thor A, Yang X. p53 inactivation upregulates p73 expression through E2F-1 mediated transcription. PLoS One. 7: e43564, 2012.

Taniguchi H, Horinaka M, Yoshida T, Yano K, Goda AE, Yasuda S, Wakada M, Sakai T. Targeting the glyoxalase pathway enhances TRAIL efficacy in cancer cells by downregulating the expression of antiapoptotic molecules. Mol Cancer Ther. 11: 2294-300, 2012.

Izutani Y, Yogosawa S, Sowa Y, Sakai T. Brassinin induces G1 phase arrest through increase of p21 and p27 by inhibition of the phosphatidylinositol 3-kinase signaling pathway in human colon cancer cells. Int J Oncol. 40: 816-24, 2012.

Horinaka M, Yoshida T, Nakata S, Shiraishi T, Tomosugi M, Yoshikawa S, Wakada M, Sakai T. Aclarubicin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis through death receptor 5 upregulation. Cancer Sci. 103: 282-7, 2012.

2011年

Yamaguchi T, Kakefuda R, Tajima N, Sowa Y, Sakai T. Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo. Int J Oncol. 39: 23-31, 2011.

Yano K, Horinaka M, Yoshida T, Yasuda T, Taniguchi H, Goda AE, Wakada M, Yoshikawa S, Nakamura T, Kawauchi A, Miki T, Sakai T. Chetomin induces degradation of XIAP and enhances TRAIL sensitivity in urogenital cancer cells. Int J Oncol. 38: 365-74, 2011.

2010年

Kawano A, Ishikawa H, Akedo I, Nakamura T, Matsumoto K, Takayama H, Imaoka A, Umesaki Y, tanaka R, Otani T, Sakai T. Effect of Lactobacillus casei on Streptococcus bovis in faecal flora. BMJ Case Reports doi: 10.1136/bcr.06.2009.2019, 2010.

Kawano A, Ishikawa H, Kamano T, Kanoh M, Sakamoto K, Nakamura T, Otani T, Sakai T, Kono K. Significance of fecal deoxycholic acid concentration for colorectal tumor enlargement. Asian Pac J Cancer P. 11: 1541-46, 2010.

Frese-Schaper M, Schardt JA, Sakai T, Carboni GL, Schmid RA, Frese S. Inhibition of tissue transglutaminase sensitizes TRAIL-resistant lung cancer cells through upregulation of death receptor 5. FEBS Lett. 584: 2867-71, 2010.

Nakamura T, Ishikawa H, Takeyama I, Kawano A, Ishiguro S, Otani T, Okuda T, Murakami Y, Sakai T, Matsuura N. Excessive fat restriction might promote the recurrence of colorectal tumors. Nutr Cancer 62: 154-63, 2010.

Koyama M, Izutani Y, Goda AE, Matsui TA, Horinaka M, Tomosugi M, Fujiwara J, Nakamura Y, Wakada M, Yogosawa S, Sowa Y, Sakai T. Histone deacetylase inhibitors and 15-deoxy-Delta12,14-prostaglandin J2 synergistically induce apoptosis. Clin Cancer Res.16, 2320-32, 2010.

Uchiyama H, Sowa Y, Wakada M, Yogosawa M, Nakanishi R, Horinaka M, Shimazaki C, Taniwaki M, Sakai T. Cyclin-dependent kinase inhibitor SU9516 enhances sensitivity to methotrexate in human T-cell leukemia Jurkat cells. Cancer Sci. 101: 728-34, 2010.

Horinaka M, Yoshida T, Kishi A, Akatani K, Yasuda T, Kouhara J, Wakada M, Sakai T. Lactobacillus strains induce TRAIL production and facilitate natural killer activity against cancer cells. FEBS Lett. 584: 577-82, 2010.

Matsui TA, Murata H, Sowa Y, Sakabe T, Koto K, Horie N, Tsuji Y, Sakai T, Kubo T. A novel MEK1/2 inhibitor induces G1/S cell cycle arrest in human fibrosarcoma cells. Oncol Rep. 24: 329-33, 2010.

Kume K, Iizumi Y, Shimada M, Ito Y, Kishi T, Yamaguchi Y, handa H. Role of N-end rule ubiquitin ligases UBR1 and UBR2 in regulating the leucine-mTOR signaling pathway. Genes Cells 15: 339-49, 2010.

Ohsaka Y, Yogosawa S, Nakanishi R, Sakai T, Nishino H. Polymorphisms in promoter sequences of the p15INK4B and PTEN genes of normal Japanese individuals. Biochem Genet. 48: 970-86, 2010.

Yasuda S, Yogosawa S, Izutani Y, Nakamura Y, Watanabe H, Sakai T. Cucurbitacin B induces G2 arrest and apoptosis via a reactive oxygen species-dependent mechanism in human colon adenocarcinoma SW480 cells. Mol Nutr Food Res. 54: 559-65, 2010.

Yoshida T, Horinaka M, Sakai T. “Combination-oriented molecular-targeting prevention” of cancer: a model involving the combination of TRAIL and a DR5 inducer. Environ Health Prev Med. 15: 203-10, 2010.

2009年

Nakamura Y, Yogosawa S, Izutani Y, Watanabe H, Otsuji E, Sakai T. A combination of indol-3-carbinol and genistein synergistically induces apoptosis in human colon cancer HT-29 cells by inhibiting Akt phosphorylation and progression of autophagy. Mol Cancer. 8: 100, 2009.

Sugiyama H, Kumamoto T, Suganami A, Nakanishi W, Sowa Y, Takiguchi M, Ishikawa T, Tamura Y. Insight into estrogenicity of phytoestrogens using in silico simulation. Biochem Biophys Res Commun. 30: 139-44, 2009.

Kikuchi H, Ohtsuki T, Koyano T, Kowithayakorn T, Sakai T, Ishibashi M. Death receptor 5 targeting activity-guided isolation of isoflavones from Millettia brandisiana and Ardisia colorata and evaluation of ability to induce TRAIL-mediated apoptosis. Bioorg Med Chem. 17: 1181-6, 2009.

Ishikawa H, Nakamura T, Kawano A, Gondo N, Sakai T. Chemoprevention of colorectal cancer in Japan: a brief introduction to current clinical trials. J Gastroenterol. 44: 77-81, 2009.

Huerta-Yepez S, Vega M, Escoto-Chavez SE, Murdock B, Sakai T, Baritaki S, Bonavida B. Nitric oxide sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of the DR5 transcription repressor Yin Yang 1. Nitric Oxide. 20: 39-52, 2009. (Epub 2008 Aug 22).

Nakayama S, Torikoshi Y, Takahashi T, Yoshida T, Sudo T, Matsushima T, Kawasaki Y, Katayama A, Gohda K, Hortobagyi GN, Noguchi S, Sakai T, Ishihara H, Ueno NT. Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells. Breast Cancer Res. 11: R12, 2009.

2008年

Yoshida T, Horinaka M, Takara M, Tsuchihashi M, Mukai N, Wakada M, Sakai T. Combination of isoliquiritigenin and tumor necrosis factor-related apoptosis-inducing ligand induces apoptosis in colon cancer HT29 cells. Environ Health Prev Med. 13: 281-7, 2008.

Kong D, Aoki S, Sowa Y, Sakai T, Kobayashi M. Smenospongine, a sesquiterpene aminoquinone from a marine sponge, induces G1 arrest or apoptosis in different leukemia cells. Mar Drugs. 6: 480-8, 2008.

Yasuda T, Yoshida T, Goda AE, Horinaka M, Yano K, Shiraishi T, Wakada M, Mizutani Y, Miki T, Sakai T. Anti-gout agent allopurinol exerts cytotoxicity to human hormone-refractory prostate cancer cells in combination with TRAIL. Mol Cancer Res. 6: 1852-60, 2008.

Taniguchi H, Yoshida T, Horinaka M, Yasuda T, Goda AE, Konishi M, Wakada M, Kataoka K, Yoshikawa T, Sakai T. Baicalein overcomes TRAIL resistance via two different cell specific pathways in cancer cells but not in normal cells. Cancer Res. 68: 8918-27, 2008.

Yoshida T, Konishi M, Horinaka M, Yasuda T, Goda AE, Taniguchi H, Yano K, Wakada M, Sakai T. Kaempferol sensitizes colon cancer cells to TRAIL-induced apoptosis. Biochem Biophys Res Commun. 375: 129-33, 2008.

Goda AE, Yoshida T, Horinaka M, Yasuda T, Shiraishi T, Wakada M, Sakai T. Mechanisms of enhancement of TRAIL tumoricidal activity against human cancer cells of different origin by dipyridamole. Oncogene. 27: 3435-45, 2008.

Shindoh N, Mori M, Terada Y, Oda K, Amino N, Kita A, Taniguchi M, Sohda KY, Nagai K, Sowa Y, Masuoka Y, Orita M, Sasamata M, Matsushime H, Furuichi K, Sakai T. YM753, a novel histone deacetylase inhibitor, exhibits antitumor activity with selective, sustained accumulation of acetylated histones in tumors in the WiDr xenograft model. Int J Oncol. 32: 545-55, 2008.

Takagi K, Sowa Y, Cevik OM, Nakanishi R, Sakai T. CDK inhibitor enhances the sensitivity to 5-fluorouracil in colorectal cancer cells. Int J Oncol. 32: 1105-10, 2008.

Matsuzaki Y, Koyama M, Hitomi T, Yokota T, Kawanaka M, Nishikawa A, Germain D, Sakai T. Arctiin induces cell growth inhibition through the down-regulation of cyclin D1 expression. Oncol Rep. 19: 721-7, 2008.

2007年

Yoshida T, Shiraishi T, Horinaka M, Nakata S, Yasuda T, Goda AE, Wakada M, Mizutani Y, Miki T, Nishikawa A, Sakai T. Lipoxygenase inhibitors induce death receptor 5/TRAIL-R2 expression and sensitize malignant tumor cells to TRAIL-induced apoptosis. Cancer Sci. 98: 1417-23, 2007.

Yoshida T, Shiraishi T, Horinaka M, Wakada M, Sakai T. Glycosylation modulates TRAIL-R1/death receptor 4 protein: different regulations of two pro-apoptotic receptors for TRAIL by tunicamycin. Oncol Rep. 18: 1239-42, 2007.

Yamaguchi T, Yoshida T, Kurachi R, Kakegawa J, Hori Y, Nanayama T, Hayakawa K, Abe H, Takagi K, Matsuzaki Y, Koyama M, Yogosawa S, Sowa Y, Yamori T, Tajima N, Sakai T. Identification of JTP-70902, a p15(INK4b)-inductive compound, as a novel MEK1/2 inhibitor. Cancer Sci. 98: 1809-16, 2007.

Matsui TA, Sowa Y, Murata H, Takagi K, Nakanishi R, Aoki S, Yoshikawa M, Kobayashi M, Sakabe T, Kubo T, Sakai T. The plant alkaloid cryptolepine induces p21WAF1/CIP1 and cell cycle arrest in a human osteosarcoma cell line. Int J Oncol. 31: 915-22, 2007.

Matsui TA, Murata H, Sakabe T, Sowa Y, Horie N, Nakanishi R, Sakai T, Kubo T. Sulforaphane induces cell cycle arrest and apoptosis in murine osteosarcoma cells in vitro and inhibits tumor growth in vivo. Oncol Rep. 18: 1263-8, 2007.

Yokota T, Matsuzaki Y, Koyama M, Hitomi T, Kawanaka M, Enoki-Konishi M, Okuyama Y, Takayasu J, Nishino H, Nishikawa A, Osawa T, Sakai T. Sesamin, a lignan of sesame, down-regulates cyclin D1 protein expression in human tumor cells. Cancer Sci. 98: 1447-53, 2007.

Koyama M, Matsuzaki Y, Yogosawa S, Hitomi T, Kawanaka M, Sakai T. ZD1839 induces p15INK4b and causes G1 arrest byinhibiting the MAPK/ERK pathway. Mol Cancer Ther. 6: 1579-87, 2007.

Liu W, Nakamura H, Yamamoto T, Ikeda N, Saito M, Ohno M, Hara N, Imanishi H, Shimomura S, Yamamoto T, Sakai T, Nishiguchi S, Hada T. Vitamin K2 inhibits the proliferation of HepG2 cells by up-regulating the transcription of p21 gene. Hepatol Res. 37: 360-5, 2007.

Yoshida T, Maoka T, Das SK, Kanazawa K, Horinaka M, Wakada M, Satomi, Y,Nishino H, Sakai T. Halocynthiaxanthin and peridinin, two dietary carotenoids, sensitize colon cancer cell lines to the death ligand TRAIL. Molecular Cancer Research. 5: 615-25, 2007.

Li Y, Mizutani Y, Shiraishi T, Nakamura T, Mikami K, Takaha N, Okihara K, Kawauchi A, Sakai T, Miki T.The significance of the expression of dihydropyrimidine dehydrogenase in prostate cancer. BJU Int. 99: 663-8, 2007.

Li Y, Mizutani Y, Shiraishi T, Okihara K, Ukimura O, Kawauchi A, Nonomura N, Fukushima M, Sakai T, Miki T. Prognostic significance of thymidylate synthase expression in patients with prostate cancer undergoing radical prostatectomy. Urology. 69: 988-95, 2007.

Baritaki S, Huerta-Yepez S, Sakai T, Spandidos DA, Bonavida B. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1. Mol Cancer Ther. 6: 1387-99, 2007.

Kouhara J, Yoshida T, Nakata S, Horinaka M, Wakada M, Ueda Y, Yamagishi H, Sakai T. Fenretinide up-regulates DR5/TRAIL-R2 expression via the induction of the transcription factor CHOP and combined treatment with fenretinide and TRAIL induces synergistic apoptosis in colon cancer cell lines. International Journal of Oncology. 30: 679-87, 2007.

Hitomi T, Matsuzaki Y, Yasuda S, Kawanaka M, Yogosawa S, Koyama M, Tantin D, Sakai T. Oct-1 is involved in the transcriptional repression of the p15(INK4b) gene. FEBS Lett. 581: 1087-92, 2007.

2006年

Izumi M, Yogosawa S, Aoki S, Watanabe H, Kamiyama J, Takahara Y, Sowa Y, Kobayashi M, Hosoi H, Sugimoto T, Sakai T. A novel synthetic drug, LB-18, closely related to lembehyne-A derived from a marine sponge, induces caspase-independent cell death to human neuroblastoma cells. Int J Oncol. 29: 169-73, 2006.

Nakata S, Yoshida T, Shiraishi T, Horinaka M, Kouhara J, Wakada M, Sakai T. 15-Deoxy-⊿^12,14-prostaglandin J₂ induces death receptor 5 expression through mRNA stabilization independently of PPARgamma and potentiates TRAIL-induced apoptosis. Mol Cancer Ther. 5: 1827-35, 2006.

Horinaka M, Yoshida T, Shiraishi T, Nakata S, Wakada M, Sakai T. The dietary flavonoid apigenin sensitizes malignant tumor cells to tumor necrosis factor-related apoptosis-inducing ligand. Mol Cancer Ther. 5:945-51, 2006.

Matsui TA, Sowa Y, Yoshida T, Murata H, Horinaka M, Wakada M, Nakanishi R, Sakabe T, Kubo T, Sakai T. Sulforaphane enhances TRAIL-induced apoptosis through the induction of DR5 expression in human osteosarcoma cells. Carcinogenesis. 27: 1768-77, 2006.

Wilson AJ, Byun DS, Popova N, Murray LB, L’Italien K, Sowa Y, Arango D, Velcich A, Augenlicht LH, Mariadason JM. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem. 281: 13548-58, 2006.

Takahara Y, Yogosawa S, Maruyama S, Watanabe N, Yokoyama H, Fukasawa K, Sukenaga Y, Kamiyama J, Izumi M, Wakada M, Zhang H, Yoshizawa K, Kawa S, Nikaido T, Sakai T. Lysocellin, a metabolite of the novel drug ‘alopestatin’, induces G1 arrest and prevents cytotoxicity induced by etoposide. Int J Oncol. 28: 823-9, 2006.

Aoki S, Kong D, Suna H, Sowa Y, Sakai T, Setiawan A, Kobayashi M. Aaptamine, a spongean alkaloid, activates p21 promoter in a p53-independent manner. Biochem Biophys Res Commun. 342: 101-6, 2006.

Hasegawa H, Yamada Y, Komiyama K, Hayashi M, Ishibashi M, Yoshida T, Sakai T, Koyano T, Kam TS, Murata K, Sugahara K, Tsuruda K, Akamatsu N, Tsukasaki K, Masuda M, Takasu N, Kamihira S. Dihydroflavonol BB-1, an extract of natural plant Blumea balsamifera, abrogates TRAIL resistance in leukemia cells. Blood. 107: 679-88, 2006.

Tabu K, Ohnishi A, Sunden Y, Suzuki T, Tsuda M, Tanaka S, Sakai T, Nagashima K, Sawa H. A novel function of OLIG2 to suppress human glial tumor cell growth via p27Kip1 transactivation. J Cell Sci. 119: 1433-41, 2006.

2005年

Fischer C, Sanchez-Ruderisch H, Welzel M, Wiedenmann B, Sakai T, Andre S, Gabius HJ, Khachigian L, Detjen KM, Rosewicz S. Galectin-1 interacts with theα5β1 fibronectin receptor to restrict carcinoma cell growth via induction of p21 and p27. J Biol Chem. 4: 37266-77, 2005.

Das SK, Hashimoto T, Shimizu K, Yoshida T, Sakai T, Sowa Y, Komoto A, Kanazawa K. Fucoxanthin induces cell cycle arrest at G(0)/G(1) phase in human colon carcinoma cells through up-regulation of p21(WAF1/Cip1). Biochim Biophys Acta. 1726: 328-35, 2005.

Shimizu K, Das SK, Hashimoto T, Sowa Y, Yoshida T, Sakai T, Matsuura Y, Kanazawa K. Artepillin C in Brazilian propolis induces G(0)/G(1) arrest via stimulation of Cip1/p21 expression in human colon cancer cells. Mol Carcinog. 44: 293-9, 2005.

Yoshida T, Maeda A, Horinaka M, Shiraishi T, Nakata S, Wakada M, Yogosawa S, Sakai T. Quercetin induces gadd45 expression through a p53-independent pathway. Oncol Rep. 14: 1299-303, 2005.

Ishihara H, Yoshida T, Kawasaki Y, Kobayashi H, Yamasaki M, Nakayama S, Miki E, Shohmi K, Matsushima T, Tada S, Torikoshi Y, Morita M, Tamura S, Hino Y, Kamiyama J, Sowa Y, Tsuchihashi Y, Yamagishi H and Sakai T.A new cancer diagnostic system based on a CDK profiling technology. BBA. 1741: 226-33, 2005.

Horinaka M, Yoshida T, Shiraishi T, Nakata S, Wakada M, Nakanishi R, Nishino H, Sakai T. The combination of TRAIL and luteolin enhances apoptosis in human cervical cancer HeLa cells. Biochem Biophys res Commun. 333: 833-8, 2005.

Horinaka M, Yoshida T, Shiraishi T, Nakata S, Wakada M, Nakanishi R, Nishino H, Matsui H, Sakai T. Luteolin induces apoptosis via death receptor 5 up-regulation in human malignant tumor cells. Oncogene. 24: 7180-9, 2005.

Shiraishi T, Yoshida T, Nakata S, Horinaka M, Wakada M, Mizutani Y, Miki T, Sakai T. Tunicamycin Enhances TRAIL-induced Apoptosis in Human Prostate Cancer Cells. Cancer Res.65: 6364-70, 2005.

Matsuzaki Y, Koyama M, Hitomi T, Takaoka Y, Kawanaka M, Sakai T. 15-deoxy-D12, 14-prostaglandin J2 activates the expression of p15INK4b gene, a cyclin-dependent kinase inhibitor. Int J Oncol. 27: 497-503, 2005.

Yoshida T, Shiraishi T, Nakata S, Horinaka M, Wakada M, Mizutani Y, Miki T, Sakai T. Proteasome inhibitor MG132 induces Death Receptor 5 through CCAAT/Enhancer-binding protein homologous protein. Cancer Res. 65: 5662-7, 2005.

Matsuzaki Y, Sakai T. INK4 Family -A promising target for ‘gene-regulating chemoprevention’ and ‘molecular-targeting prevention’ of cancer. Environ Health Prev Med. 10: 72-7, 2005.

Maeda T, Nagaoka Y, Kawai Y, Takagaki N, Yasuda C, Yogosawa S, Sowa Y, Sakai T, Uesato S. Inhibitory effects of cancer cell proliferation by novel histone deacetylase inhibitors involve p21/WAF1 induction and G2/M arrest. Biol Pharm Bull. 28: 849-53, 2005.

Murata K, Hattori M, Hirai N, Shinozuka Y, Hirata H, Kageyama R, Sakai T, Minato N. Hes1 directly controls cell proliferation through the transcriptional repression of p27Kip1. Mol Cell Biol. 25: 4262-71, 2005.

Shiraishi T, Yoshida T, Nakata S, Horinaka M, Wakada M, Mizutani Y, Miki T, Sakai T. Differential response at the hGABP/E4TF1 site of retinoblastoma gene promoter in human testicular seminoma cells. Oncol Rep. 13: 871-4, 2005.

Takagaki N, Sowa Y, Oki T, Nakanishi R, Yogosawa S, Sakai T. Apigenin induces cell cycle arrest and p21/WAF1 expression in a p53-independent pathway. Int J Oncol. 26: 185-9, 2005.

Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, Perez G, Ngo L, Holmgren A, Jiang X, Marks PA. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci U S A. 102: 673-8, 2005.

2004年

Matsuzaki Y, Koyama M, Hitomi T, Kawanaka M, Sakai T. Indole-3-carbinol activates the cyclin-dependent kinase inhibitor p15(INK4b) gene. FEBS Lett. 576: 137-40, 2004.

Oki T, Sowa Y, Hirose T, Takagaki N, Horinaka M, Nakanishi R, Yasuda C., Yoshida T, Kanazawa M, Satomi Y, Nishino H, Miki T, Sakai T. Genistein Induces Gadd45 Gene and G2/M Cell Cycle Arrest in the DU145 Human Prostate Cancer Cell Line FEBS Lett. 577: 55-9, 2004.

Yokota T, Matsuzaki Y, Sakai T. Trichostatin A activates p18(INK4c) gene: differential activation and cooperation with p19(INK4d) gene. FEBS Lett. 574: 171-5, 2004.

Nakata S, Yoshida T, Horinaka M, Shiraishi T, Wakada M, Sakai T. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene. 23: 6261-71, 2004.

Sakata R, Minami S, Sowa Y, Yoshida M, Tamaki T. Trichostatin A activates the osteopontin gene promoter through AP1 site. Biochem Biophys Res Commun. 315: 959-63, 2004.

Yokota T, Matsuzaki Y, Miyazawa K, Zindy F, Roussel MF, Sakai T. Histone deacetylase inhibitors activate INK4d gene through Sp1 site in its promoter. Oncogene. 23: 5340-9, 2004.

Matsuzaki Y, Takaoka Y, Hitomi T, Nishino H, Sakai T. Activation of protein kinase C promotes human cancer cell growth through downregulation of p18(INK4c). Oncogene. 23: 5409-14, 2004.

Yoshida T, Sakai T. Promoter of TRAIL-R2 gene. Vitamins and Hormones. 67: 35-49, 2004.

2003年

Hitomi T, Matsuzaki Y, Yokota T, Takaoka Y, Sakai T. p15(INK4b) in HDAC inhibitor-induced growth arrest. FEBS Lett. 554: 347-50, 2003.

Hirose T, Sowa Y, Takahashi S, Saito S, Yasuda C, Shindo N, Furuichi K, Sakai T. p53-independent induction of Gadd45 by histone deacetylase inhibitor: coordinate regulation by transcription factors Oct-1 and NF-Y. Oncogene. 22: 7762-73, 2003.

Saito S, Takahashi S, Takagaki N, Hirose T, Sakai T. 15-Deoxy-Delta(12,14)-prostaglandin J2 induces apoptosis through activation of the CHOP gene in HeLa cells. Biochem Biophys Res Commun. 311: 17-23, 2003.

Kanazawa M, Satomi Y, Mizutani Y, Ukimura O, Kawauchi A, Sakai T, Baba M, Okuyama T, Nishino H, Miki T. Isoliquiritigenin inhibits the growth of prostate cancer. European Urology. 43: 580-6, 2003.

Bruemmer D, Yin F, Liu J, Berger J.P, Sakai T, Blaschke F, Fleck E, Van Herle A.J, Forman B.M, Law R.E. Regulation of the growth arrest and DNA damage-inducible gene 45 (GADD45) by peroxisome proliferator-activated receptor gamma in vascular smooth muscle cells. Circulation Research. 93: 38-47, 2003.

Marabese M, Vikhankaya F, Rainelli C, Sakai T, Broggini M. DNA damage induces transcriptional activation of p73 by removing C-EBPa repression on E2F1. Nucleic Acids Research. 31: 6624-32, 2003.

Matsuzaki Y, Sowa Y, Hirose T, Yokota T, Sakai T, Broggini M. Histone deacetylase inhibitors-Promising agents for “Gene-regulating chemoprevention” and Molecular-targeting preventionﾓ of cancer-. Environmental Health and Preventive Medicine. 8: 157-60, 2003.

2002年

Matsukawa Y, Nishino H, Yoshida M, Sugihara H, Katsura K, Takamatsu T, Okuzumi J, Matsumoto K, Sato-Nishimori F, Sakai T. Quercetin enhances tumorigenicity induced by N-ethyl-N’-nitro-N-nitrosoguanidine in the duodenum of mice. Environ Health Prev Med. 6: 235-9, 2002.

Matsuzaki Y, Miyazawa K, Yokota T, Hitomi T, Yamagishi H, Sakai T. Molecular cloning and characterization of the human p19(INK4d) gene promoter. FEBS Lett. 517: 272-6, 2002.

Maeda A, Yoshida T, Kusuzaki K, Sakai T. The characterization ofthe human Siah-1 promoter. FEBS Lett. 512: 223-6, 2002.

Brooks L.A, Sullivan A, O’Nions J, Bell A, Dunne B, Tidy J.A, Evans D.J, Osin P, Vousden K.H, Gusterson B, Farrell P.J, Storey A, Gasco M, Sakai T, Crook T. E7 proteins from oncogenic human papillomavirus types transactivate p73: role in cervical intraepithelial neoplasia. Br J Cancer. 86: 263-8, 2002.

2001年

Takakura M, Kyo S, Sowa Y, Wang Z, Yatabe N, Maida Y, Tanaka M, Inoue M. Telomerase activation by histone deacetylase inhibitor in normal cells. Nucleic Acids Res. 29: 3006-11, 2001.

Yoshida T, Maeda A, Tani N, Sakai T. Promoter structure and transcription initiation sites of the human Death Receptor 5/TRAIL-R2 gene. FEBS Lett. 507: 381-5, 2001.

Matikainen T, Perez G.I, Jurisicova A, Pru J.K, Schlezinger J.J, Ryu H.Y, Laine J, Sakai T, Korsmeyer S.J, Casper R.F, Sherr D.H, Tilly J.L. Aromatic hydrocarbon receptor-driven Bax gene expression is required for premature ovarian failure caused by biohazardous environmental chemicals. Nat Genet. 28: 355-60, 2001.

Takahashi S, Saito S, Ohtani N, Sakai T. Involvement of the Oct-1 regulatory element of the gadd45 promoter in the p53-independent response to ultraviolet irradiation. Cancer Res. 61: 1187-95, 2001.

Kanemitsu N, Kato M.V, Bai F, Miki T, Inoue T, Sakai T. Correlation between induction of the mac25 gene and anti-proliferative effects of 1alpha,25(OH)2-D3 on breast cancer and leukemic cells. Int J Mol Med. 7: 515-20, 2001.

Onishi K, Kato M.V, Bai F, Sakai T. SMRT as a T3SF-binding protein. Int J Oncol. 18: 985-9, 2001.

2000年

Kanemitsu N, Kato M.V, Miki T, Komatsu S, Okazaki Y, Hayashizaki Y, Sakai T. Characterization of the promoter of the murine mac25 gene. Biochem Biophys Res Commun. 279: 251-7, 2000.

Huang L, Sowa Y, Sakai T, Pardee A.B. Activation of the p21/WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites. Oncogene. 19: 5712-9, 2000.

Sowa Y, Sakai T. Butyrate as a model for “gene-regulating chemoprevention and chemotherapy.”. Biofactors. 12: 283-7, 2000.

Evdokiou A, Raggatt L.J, Sakai T, Findlay D.M. Identification of a novel calcitonin-response element in the promoter of the human p21WAF1/CIP1 gene. J Mol Endocrinol. 25: 195-206, 2000.

Sasaki K, Tamura S, Tachibana H, Sugita M, Gao Y, Furuyama J, Kakishita E, Sakai T, Tamaoki T, Hashimoto-Tamaoki T. Expression and role of p27(kip1) in neuronal differentiation of embryonal carcinoma cells. Brain Res Mol Brain Res. 77: 209-21, 2000.

Uno K, Azuma T, Nakajima M, Yasuda K, Hayakumo T, Mukai H, Sakai T, Kawai K. Clinical significance of cathepsin E in pancreatic juice in the diagnosis of pancreatic ductal adenocarcinoma. J Gastroenterol Hepatol. 15: 1333-8, 2000.

1999年

Ueno M, Masutani H, Arai R.J, Yamauchi A, Hirota K, Sakai T, Inamoto T, Yamaoka Y, Yodoi J, Nikaido T. Thioredoxin-dependent redox regulation of p53-mediated p21 activation. J Biol Chem. 274: 35809-15, 1999.

Inoue T, Kamiyama J, Sakai T. Sp1 and NF-Y synergistically mediate the effect of vitamin D3 in the p27Kip1 gene promoter that lacks vitamin D response elements. J Biol Chem. 274: 32309-17, 1999.

Igata E, Inoue T, Ohtani-Fujita N, Sowa Y, Tsujimoto Y, Sakai T. Molecular cloning and functional analysis of the murine bax gene promoter. Gene. 238: 407-15, 1999.

Ding Y, Inoue T, Kamiyama J, Tamura Y, Ohtani-Fujita N, Igata E, Sakai T. Molecular cloning and functional characterization of the upstream promoter region of the human p73 gene. DNA Res. 6: 347-51, 1999.

Ding Y, Matsukawa Y, Ohtani-Fujita N, Kato D, Dao S, Fujii T, Naito Y, Yoshikawa T, Sakai T, Rosenthal G.A. Rosenthal G.A. Growth inhibition of A549 human lung adenocarcinoma cells by L-canavanine is associated with p21/WAF1 induction. Jpn J Cancer Res. 90: 69-74, 1999.

Kamiyama J, Inoue T, Ohtani-Fujita N, Minami S, Yamagishi H, Sakai T. The ubiquitous transcription factor NF-Y positively regulates the transcription of human p27Kip1 through a CCAAT box located in the 5-upstream region of the p27Kip1 gene. FEBS Lett. 455: 281-5, 1999.

Fujita T, Ohtani-Fujita N, Sakai T, Rapaport J.M, Dryja T.P, Kato M.V, Ishizaki K, Sasaki M.S, Hotta Y, Maeda K, Kinoshita S, Ohnishi Y, Minoda K. Low frequency of oncogenic mutations in the core promoter region of the RB1 gene. Hum Mutat. 13: 410-1, 1999.

Sowa Y, Orita T, Minamikawa-Hiranabe S, Mizuno T, Nomura H, Sakai T. Sp3, but not Sp1, mediates the transcriptional activation of the p21/WAF1/Cip1 gene promoter by histone deacetylase inhibitor. Cancer Res. 59: 4266-70, 1999.

Sowa Y, Orita T, Hiranabe-Minamikawa S, Nakano K, Mizuno T, Nomura H, Sakai T. Histone deacetylase inhibitor activates the p21/WAF1/Cip1 gene promoter through the Sp1 sites. Ann N Y Acad Sci. 886: 195-9, 1999.

1998年

Tamura Y, Sugimoto M, Ohnishi K, Sakai T, Hara E. Differential activity of a variant form of the human Id-1 protein generated by alternative splicing. FEBS Lett. 436: 169-73, 1998.

Matsumoto T, Ohtani-Fujita N, Sowa Y, Bai F, Nikaido T, Tamaki T, Sakai T. Cell cycle-dependent modulation of promoter activities of RB and WAF1/Cip1 genes. Jpn J Cancer Res. 89: 626-33, 1998.

Matsumoto T, Sowa Y, Ohtani-Fujita N, Tamaki T, Takenaka T, Kuribayashi K, Sakai T. p53-independent induction of WAF1/Cip1 is correlated with osteoblastic differentiation by vitamin D3. Cancer Lett. 129: 61-8, 1998.

Ohtani-Fujita N, Minami S, Mimaki S, Dao S, Sakai T. p53 independent activation of the gadd45 promoter by ⊿¹²-prostaglandin J₂. Biochem. Biophys. Res. Commun. 251: 648-52, 1998.

Bai F, Matsui T, Ohtani-Fujita N, Matsukawa Y, Ding Y, Sakai T. Promoter activation and following induction of the p21/WAF1 gene by flavone is involved in G1 phase arrest in A549 lung adenocarcinoma cells. FEBS Lett. 437: 61-4, 1998.

Kato D, Miyazawa K, Ruas M, Starborg M, Wada I, Oka T, Sakai T, Peters G, Hara E. Features of replicative senescence induced by direct addition of antennapedia-p16INK4A fusion protein to human diploid fibroblasts. FEBS Lett. 427: 203-208, 1998.

1997年

Matsukawa Y, Nishino H, Okuyama Y, Matsui T, Matsumoto T, Matsumura S, Shimizu Y, Sowa Y, Sakai T. Effects of quercetin and/or restraint stress on formation of aberrant crypt foci induced by azoxymethane in rat colons. Oncology. 54: 118-121, 1997.

Nakano K, Mizuno T, Sowa Y, Orita T, Yoshino T, Okuyama Y, Fujita T, Ohtani-Fujita N, Matsukawa Y, Tokino T, Yamagishi H, Oka T, Nomura H, Sakai T. Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line. The Journal of Biological Chemistry. 272: 22199-206, 1997.

Minami S, Ohtani-Fujita N, Igata E, Tamaki T, Sakai T. Molecular cloning and characterization of the human p27Kip1 gene promoter. FEBS Letters. 411: 1-6, 1997.

Sowa Y, Shiio Y, Fujita T, Matsumoto T, Okuyama Y, Kato D, Inoue J, Sawada J, Goto M, Watanabe H, Handa H, Sakai T. Retinoblastoma binding factor 1 site in the core promoter region of the human RB gene is activated by hGABP/E4TF1. Cancer Research. 57: 3145-8, 1997.

Matsui T, Matsukawa Y, Sakai T, Nakamura K, Aoike A, Kawai K. Ammonia inhibits proliferation and cell cycle progression at S-phase in human gastric cells. Digestive Diseases and Sciences. 42: 1394-9, 1997.

Sowa Y, Orita T, Minamikawa S, Nakano K, Mizuno T, Nomura H, Sakai T. Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochemical and Biophysical Research Communications. 241: 142-50, 1997.

Ohtani-Fujita N, Dryja T.P, Rapaport J.M, Fujita T, Matsumura S, Ozasa K, Watanabe Y, Hayashi K, Maeda K, Kinoshita S, Matsumura T, Ohnishi Y, Hotta Y, Takahashi R, Kato M.V, Ishizaki K, Sasaki M.S, Horsthemke B, Minoda K, Sakai T. Hypermethylation in the retinoblastoma gene is associated with unilateral, sporadic retinoblastoma. Cancer Genetics and Cytogenetics. 98: 43-9, 1997.

1996年

Fujita T, Ohtani-Fujita N, Sakai T. Identification of an RB-responsive region in the 5′ untranslated region of the RB gene. Cancer Letters. 101: 149-57, 1996.

Okuyama Y, Sowa Y, Fujita T, Mizuno T, Nomura H, Nikaido T, Endo T, Sakai T. ATF site of human RB gene promoter is a responsive element of myogenic differentiation. FEBS Letters. 397: 219-24, 1996.

Nikaido T, Ono K, Yamamoto M, Sakai T, Magami Y. Cell cycle regulation in T-cells．Matsumoto Symposium: Epithelial & Lymphoid Cell Cohabitation for Mucosal Immunity． Amsterdam : Elsevier Science. (in the press)

Matsukawa Y, Sato F, Sakai T. Effects of flavonoids on cell cycle and differentiation in cancer cells．Proceedings of International Conference on Food Factors-Chemistry and Cancer Prevention- (Osawa, T., editor)． Tokyo : Springer-Verlag, (in the press).

1995年

Matsui T, Matsukawa Y, Sakai T, Nakamura K, Aoike A, Kawai K. Effect of ammonia on cell-cycle progression of human gastric cancer cells． Eur J Gastroenterol Hepatol , 7, S79-S81, 1995.

1994年

Yamamoto M, Yoshida M, Ono K, Fujita T, Ohtani-Fujita N, Sakai T, Nikaido T. Effect of tumor suppressors on cell cycle-regulatory genes: RB suppresses p34cdc2 expression and normal p53 suppresses cyclin A expression. Experimental Cell Research. 210: 94-101, 1994.

Osifchin N.E, Jiang D, Ohtani-Fujita N, Fujita T, Carroza M, Kim S.-J, Sakai T, Robbins P.D. Identification of a p53 binding site in the human retinoblastoma susceptibility gene promoter. The Journal of Biological Chemistry. 269: 6383-9, 1994.

Ohtani-Fujita N, Fujita T, Takahashi R, Robbins P.D, Dryja T.P, Sakai T. A silencer element in the retinoblastoma tumor-suppressor gene. Oncogene. 9: 1703-11, 1994.

Savoysky E, Mizuno T, Sowa Y, Watanabe H, Sawada J.-i, Nomura H, Ohsugi Y, Handa H, Sakai T. The retinoblastoma binding factor 1 (RBF-1) site in RB gene promoter binds preferentially E4TF1, a member of the Ets transcription factors family. Oncogene. 9: 1839-46, 1994.

Sato F, Matsukawa Y, Matsumoto K, Nishino H, Sakai T. Apigenin induces morphological differentiation and G2-M arrest in rat neuronal cells. Biochemical and Biophysical Research Communications. 204: 578-84, 1994.

Nikaido T, Ono K, Yamamoto M, Sakai T, Magami Y. Cell cycle regulation in normal versus leukemic　T cells. The Cell Cycle: Regulators, Targets, and Clinical Applications (Hu, V.W., editor). New York and London : Plenum Press, 347-57, 1994

1993年

Ohtani-Fujita N, Fujita T, Aoike A, Osifchin N.E, Robbins P.D, Sakai T. CpG methylation inactivates the promoter activity of the human retinoblastoma tumor-suppressor gene. Oncogene. 8: 1063-7, 1993.

Matsukawa Y, Marui N, Sakai T, Satomi Y, Yoshida M, Matsumoto K, Nishino H, Aoike A. Genistein arrests cell cycle progression at G2-M. Cancer Research. 53: 1328-31, 1993.

Yamamoto M, Marui N, Sakai T, Morii N, Kozaki S, Ikai K, Imamura S, Narumiya S. ADP-ribosylation of the rho A gene product by botulinum C3 exoenzyme causes Swiss 3T3 cells to accumulate in the G1 phase of the cell cycle. Oncogene. 8: 1449-55, 1993.

1992年

Yoshida M, Marui N, Sakai T, Hosokawa N, Matsukawa Y, Aoike A, Kawai K. Reversible arrest of proliferation of the gastric cancer cells in the G1 phase by quercetin．Cytoprotection and Cytobiology (Tobe, T., editor)，Tokyo : Kanishobo, 8: 185-91, 1992.

1991年

Marui N, Nishino H, Sakai T, Aoike A, Kawai K, Fukushima M. ⊿¹²-prostaglandin J₂ mimics heat shock in inducing cell cycle arrest at G1 phase. Biochemical and Biophysical Research Communications. 179: 1662-9, 1991.

Sakai T, Toguchida J, Ohtani N, Yandell D.W, Rapaport J.M, Dryja T.P.　Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. The American Journal of Human Genetics. 48: 880-8, 1991.

Sakai T, Ohtani N, McGee T.L, Robbins P.D, Dryja T.P. Oncogenic germ-line mutations in Sp1 and ATF sites in the human retinoblastoma gene. Nature. 353: 83-6, 1991.

1990年

Yoshida M, Sakai T, Hosokawa N, Marui N, Matsumoto K, Fujioka A, Nishino H, Aoike A. The effect of quercetin on cell cycle progression and growth of human gastric cancer cells. FEBS Letters. 260: 10-3, 1990.

Marui N, Sakai T, Hosokawa N, Yoshida M, Aoike A, Kawai K, Nishino H, Fukushima M. N-myc suppression and cell cycle arrest at G1 phase by prostaglandins. FEBS Letters. 270: 15-8, 1990.

Hosokawa N, Hosokawa Y, Sakai T, Yoshida M, Marui N, Nishino H, Kawai K, Aoike A. Inhibitory effect of quercetin on the synthesis of a possibly cell-cycle-related 17-kDa protein, in human colon cancer cells. International Journal of Cancer. 45: 1119-24, 1990.

Hosokawa N, Hirayoshi K, Nakai A, Hosokawa Y, Marui N, Yoshida M, Sakai T, Nishino H, Aoike A, Kawai K, Nagata K. Flavonoids inhibit the expression of heat shock proteins. Cell Structure and Function. 15: 393-401, 1990.

1989年

Sakai T, Aoike A, Marui N, Kawai K, Nishino H, Fukushima M. Protection by cycloheximide against cytotoxicity induced by vincristine, colchicine, or ⊿¹²– prostaglandin J₂ on human osteosarcoma cells. Cancer Research. 49: 1193-6, 1989.

Murakoshi M, Takayasu J, Kimura O, Kohmura E, Nishino H, Iwashima A, Okuzumi J, Sakai T, Sugimoto T, Imanishi J, Iwasaki R.　Inhibitory effects of α-carotene on proliferation of the human neuroblastoma cell line GOTO. Journal of the National Cancer Institute. 81: 1649-52, 1989.

Sakai T, Aoike A, Marui N, Nishino H, Fukushima M, Kawai K. Cytoprotective effect of cycloheximide against cytotoxicity induced by anti-tumor drugs．Cytoprotection and Cytobiology (Nagamachi, Y., editor). London : Cytomedica 6: 171-6, 1989.

和文総説・著書

曽和義広, 酒井敏行.　がん抑制遺伝子とヘルスフード.　水島裕監修. アンチエイジング・ヘルスフード.　東京：サイエンスフォーラム, 261-7, 2008.

堀中真野, 酒井敏行. 食品成分による癌の「分子標的予防法」の開発.　FFIジャーナル213：537-44, 2008.

曽和義広, 酒井敏行.　発癌の分子機構に基づいた癌の“分子標的予防”研究.　医学のあゆみ　227：147-8, 2008.

与五沢真吾. 　田村隆明、山本雅之編.　転写因子・転写制御キーワードブック. 東京：羊土社, 132-3, 225, 233, 261, 303-4, 306, 2006.

吉田達士. 　田村隆明、山本雅之編.　転写因子・転写制御キーワードブック. 東京：羊土社, 113-4, 154-5, 174, 243-4, 2006.

与五沢真吾、西野輔翼、酒井敏行.　ヒトがん化学予防研究への応用.　がん分子標的治療　2 : 60-6, 2004

曽和義広、酒井敏行.　癌の化学療法・予防法へのゲノミクスの利用.　生体の科学　54: 386-92, 2003.

曽和義広、酒井敏行.　癌の遺伝子調節化学予防法ー癌の「分子標的予防法」のモデルとしてー　日本衛生学雑誌　58: 267-4, 2003.

神山順、酒井敏行.　遺伝子調節化学予防　発癌の遺伝子異常に基づいた新しい予防法の開発. 医学のあゆみ　204: 3-6, 2003.

酒井敏行、神山順、曽和義広.　発癌感受性に対する食物成分による分子修飾.　癌の臨床　46: 1421-4, 2000.

曽和義広、酒井敏行. p53とp21/WAF1を標的とした分子治療.　現代医療　32：2406-10, 2000.

酒井敏行. がんの遺伝子調節化学予防（化学療法）. 西野輔翼編. がん化学予防の最前線. 大阪：医療ジャーナル社, 95-103, 2000.

酒井敏行.　悪性腫瘍.　各論３　成人病・生活習慣病,　アレルギー疾患 molecular pathogenesis から chemopreventionまで.　分子予防医学.　東京、医学書院、254-9, 1999.

曽和義広、酒井敏行.　がん予防－分子レベルのメカニズム. 大澤　俊彦、大東肇、吉川敏一. 監修. がん予防食品：フードファクターの予防医学への応用.　　東京、株式会社シーエムシー、　53-64, 1999.

酒井敏行.　要因観察方法の推移．特集/日本がん疫学研究会の２０年と課題．　癌の臨床．44；35-38, 1998.

中野且敬、山岸　久一、岡　隆宏、酒井　敏行.　遺伝子調節による予防.　日本外科学会雑誌.　99：373-8, 1998.

内藤祐二、酒井敏行.　胃癌・消化性潰瘍の遺伝について. 内科診療Q&A. 名古屋：六法出版社, 174-7, 1997.

酒井敏行.　分子癌疫学－その現状および今後の可能性．第65回日本衛生学会奨励賞受賞講演総説．日本衛生学雑誌　50：1036-46, 1996.

酒井敏行.　ｐ５３によるＲＢ遺伝子の発現制御．実験医学　13：45-8, 1995.

藤田直子、酒井敏行.　ＲＢ遺伝子のエピジェネティックな異常による発癌の可能性．実験医学　13：80(1448)-82(1450), 1995.

酒井敏行.　癌予防と早期発見へのアプローチ－癌予防法の開発．予防医学と分子生物学．公衆衛生　59：832-3, 1995.

酒井敏行.　遺伝学のトピックス、癌抑制遺伝子とは?　の項担当．眼科診療プラクティス、眼科診療に役立つ遺伝学（大庭紀雄編集）．東京：文光堂，114-5, 1995.

松川義純、酒井敏行、佐藤婦美子、川井啓市．フラボノイド類の細胞周期に及ぼす影響とがん予防．がん予防食品の開発（大澤俊彦編集）．東京：シーエムシー社，101-109, 1995.

酒井敏行．遺伝子調節化学予防の基礎的研究．がん増殖の抑制と食品との関連（川井啓市監修、青池　晟、渡邊能行、酒井敏行編集）．東京：ライフサイエンス出版，11-3, 1995.

松川義純、酒井敏行、佐藤婦美子、川井啓市．フラボノイドによる発がん抑制およびそのメカニズム．がん増殖の抑制と食品との関連（監修、青池　晟、渡邊能行、酒井敏行編集）．東京：ライフサイエンス出版，53-6, 1995.

酒井敏行、川井啓市．第V 章、胃癌、b. 遺伝子レベルでの発生論の項担当．胃－形態とその機能（第２版）（川井啓市編集）．東京：医学書院，326-30, 1994.

酒井敏行、川井啓市.　公衆衛生学的に有用な新しい癌体質診断法の開発．病態生理　13：468-72, 1994.

酒井敏行：シグナル伝達異常と疾病．IV. 転写因子ＲＢと網膜芽細胞腫．臨床科学　30：1242-8, 1994.

松井亮好、松川義純、酒井敏行、中村圭也、青池晟、川井啓市．アンモニアのヒト胃癌培養細胞の細胞周期に与える影響．Cyto-protection and biology（中村紀夫編集）．東京：癌と化学療法社，12, 15-8, 1994.

松川義純、酒井敏行、東健、青池晟、川井啓市.　消化性潰瘍の遺伝子解析．臨床科学　29：862-6, 1993.

酒井敏行.　ＲＢ遺伝子のプロモーター構造およびその不活性化機構．癌抑制遺伝子－その作用機構に迫る（野田亮編集）．東京：羊土社，10 ，16(2142)-21(2147), 1992.

吉田光範、丸井伸行、酒井敏行、細川暢子、松川義純、青池晟、川井啓市．植物性フラボノイド(quercetin) のヒト胃癌培養細胞増殖に対する抑制効果－特に細胞周期に及ぼす影響について－．Cyto-protection & biology（戸部隆吉ら編）．東京：蟹書房，8，209-16, 1990.